For example, two epidermal growth factor receptor (HER1) tyrosine kinase inhibitors (TKI), Gefitinib (Iressa) and Erlotinib (Tarceva), have been FDA approved for the treatment of locally advanced or metastatic NSCLC that has failed at least one prior chemotherapy regimen [5, 6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.